Posted by Michael Wonder on 04 Oct 2024
Blue Shield of California slashes cost of world's best selling drug
1 October 2024 - Non-profit health plan collaborates with Fresenius Kabi and Evio Pharmacy Solutions to purchase FDA approved Humira biosimilar for $525 per monthly dose, compared to the market reported net price of Humira at $2,100.
Blue Shield of California today announced it has drastically cut the price it will pay for an FDA approved biosimilar of blockbuster drug Humira – purchasing the medicine at a transparent net price of $525 per monthly dose, compared to the market reported net price of Humira at $2,100.
